Related Experiment Video
Updated: Jan 19, 2026
Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
Published on: May 3, 2018
Recent advances in the development of cyclin-dependent kinase 7 inhibitors
Yuou Teng1, Kui Lu1, Qian Zhang1
1China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China.
Abstract:
Cyclin dependent kinase 7 (CDK7) plays a double role as it activates several other cyclin dependent kinases and participates to the initiation of transcription. This kinase is overexpressed in various types of tumors. Relatively few selective CDK7 inhibitors have been up to now disclosed. Most of these inhibitors belong to two chemical families: pyrazolopyrimidines and pyrazolotriazines on one side and pyrimidines on another side. They also differ by their molecular mechanism of action. Some are acting as competitive inhibitors and some others are covalent inhibitors. With these tools, the understanding of the potential therapeutic interest of CDK7 inhibitors in cancer is rapidly growing. They display antiproliferative activity against various types of tumors and leukemia and synergies have been identified. Two inhibitors are undergoing clinical testing. The most potent compounds inhibit a large number of cell-lines with IC50 < 200 nM.
Insights
Selective cyclin-dependent kinase 7 (CDK7) inhibitors show promise for cancer therapy. These compounds exhibit antiproliferative effects and are advancing into clinical trials for various malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Medicinal Chemistry
Background:
- Cyclin-dependent kinase 7 (CDK7) is overexpressed in numerous cancers.
- CDK7 regulates cell cycle progression and transcription initiation.
- Targeting CDK7 offers a potential therapeutic strategy for cancer treatment.
Purpose of the Study:
- To review the landscape of selective CDK7 inhibitors.
- To discuss their chemical classes and mechanisms of action.
- To highlight their therapeutic potential in oncology.
Main Methods:
- Literature review of CDK7 inhibitors.
- Analysis of chemical structures and mechanisms.
- Summary of preclinical and clinical findings.
Main Results:
- Few selective CDK7 inhibitors are available, primarily pyrazolopyrimidines, pyrazolotriazines, and pyrimidines.
- Inhibitors act via competitive or covalent mechanisms.
- Potent inhibitors show antiproliferative activity (IC50 < 200 nM) against various cancer cell lines.
- Synergistic effects observed with other agents.
- Two inhibitors are currently in clinical trials.
Conclusions:
- CDK7 inhibitors represent a promising class of anticancer agents.
- Further research and clinical evaluation are warranted.
- These inhibitors have demonstrated significant potential in preclinical cancer models.
Related Concept Videos
12:26Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
13:22Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
06:42Identifying Kinase Inhibitors that Modulate the Thymocyte Response to Strong TCR Signals
06:06Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
07:18A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening